Hematological Malignancies

Hematological Malignancies

Hematological Malignancies

On this page

Heme Malignancies Overview - Blood Cell Chaos

  • Cancers of blood, bone marrow, lymphoid system; uncontrolled proliferation of abnormal hematopoietic/lymphoid cells.
  • Broadly classified by:
    • Cell Lineage: Myeloid (affecting RBCs, granulocytes, monocytes, platelets) vs. Lymphoid (affecting lymphocytes).
    • Maturity & Onset:
      • Acute: Rapid progression, immature cells (blasts). WHO defines AML/ALL with ≥20% blasts in marrow/blood.
      • Chronic: Slower progression, more differentiated cells.
  • Common presentations: Cytopenias (anemia, infections, bleeding), B-symptoms (fever, night sweats, weight loss), organomegaly.
  • Diagnosis: CBC, peripheral smear, bone marrow aspiration & biopsy, immunophenotyping, cytogenetics, molecular studies.

Peripheral blood smear showing blasts

⭐ Auer rods (needle-like granules in cytoplasm) are pathognomonic for Acute Myeloid Leukemia (AML), especially Acute Promyelocytic Leukemia (APML).

Leukemias Unmasked - Proliferation Pandemonium

Uncontrolled WBC precursor proliferation. Acute (>20% marrow blasts) vs. Chronic. Myeloid vs. Lymphoid origin.

  • AML (Acute Myeloid Leukemia): Adults. Auer rods (MPO+). 📌 Auer Makes Leukemia. APML t(15;17) responsive to ATRA. Gingival hypertrophy (M4/M5).
  • ALL (Acute Lymphoblastic Leukemia): Children. TdT+. CNS prophylaxis crucial. Good prognosis. Philadelphia chr. t(9;22) variant = poor outcome.
  • CML (Chronic Myeloid Leukemia): Adults. Hallmark: Philadelphia chr. t(9;22) (BCR-ABL1). TKIs mainstay. ↓LAP score. Blast crisis risk.

    ⭐ The Philadelphia chromosome t(9;22), creating BCR-ABL1 fusion, is pathognomonic for CML.

  • CLL (Chronic Lymphocytic Leukemia): Elderly. Most common adult leukemia (West). Mature B-cells. Smudge cells on smear. Often indolent. Richter's transformation (DLBCL).

Auer rods in AML peripheral blood smear

Lymphoma Lowdown - Nodal Nightmares

  • Clonal proliferations of mature lymphocytes; nodal/extranodal.
  • Hodgkin Lymphoma (HL):
    • Key: Reed-Sternberg (RS) cells (CD15+, CD30+).
    • Age: Bimodal (15-35 & >50 yrs).
    • Spread: Contiguous, orderly. Staging: Ann Arbor.
    • Rx: ABVD regimen. Generally good prognosis.
  • Non-Hodgkin Lymphoma (NHL):
    • More common, diverse (B-cell ~85%, T-cell ~15%).
    • Spread: Non-contiguous, often widespread at diagnosis.
    • Types: Aggressive (e.g., DLBCL - Rx: R-CHOP) vs. Indolent (e.g., Follicular - t(14;18) BCL2).

⭐ Burkitt Lymphoma (NHL): "Starry sky" histology; t(8;14) c-MYC. Endemic (jaw), Sporadic (abdomen).

Reed-Sternberg cells with LMP1 and CD30 staining

📌 B-Symptoms: Unexplained Fever >38°C, Drenching Night Sweats, Weight Loss >10% in 6 months.

Myeloma & MPN/MDS Mix - Marrow Madness Medley

  • Multiple Myeloma (MM): Malignant plasma cells in marrow.

    • CRAB criteria: ↑Ca²⁺ (>11mg/dL), Renal insufficiency (CrCl <40mL/min), Anemia (Hb <10g/dL), Bone lesions (lytic).
    • Myeloma Defining Events (MDEs): ≥60% marrow plasma cells, Serum Free Light Chain (FLC) ratio ≥100, >1 focal lesion on MRI.
    • M-spike (IgG>IgA), Bence-Jones proteinuria. Rouleaux formation.
    • Multiple myeloma skull X-ray with lytic lesions
  • Myeloproliferative Neoplasms (MPN): Clonal myeloid cell overproduction.

    • Key mutations: JAK2 V617F (Polycythemia Vera (PV) >95%; Essential Thrombocythemia (ET)/Primary Myelofibrosis (PMF) ~50%), CALR, MPL.
    • PV: ↑RBC mass, ↓EPO. ET: ↑Platelets. PMF: Marrow fibrosis, splenomegaly, teardrop cells.

    ⭐ Philadelphia chromosome (t(9;22), BCR-ABL1) defines Chronic Myeloid Leukemia (CML), an MPN responsive to Tyrosine Kinase Inhibitors (e.g., Imatinib).

  • Myelodysplastic Syndromes (MDS): Ineffective hematopoiesis, cytopenias, marrow dysplasia.

    • Risk of Acute Myeloid Leukemia (AML) transformation.
    • Features: Pseudo-Pelger-Huët anomaly (bilobed neutrophils), ring sideroblasts.
    • 5q- syndrome: specific subtype with isolated del(5q), good prognosis, Lenalidomide-sensitive.

High‑Yield Points - ⚡ Biggest Takeaways

  • Hodgkin Lymphoma: Reed-Sternberg cells (CD15+, CD30+) are pathognomonic.
  • Multiple Myeloma: Defined by CRAB criteria, M-spike, and Bence Jones proteins.
  • CML: Philadelphia chromosome t(9;22) (BCR-ABL1) is characteristic; Imatinib is key therapy.
  • AML: >20% blasts in bone marrow for diagnosis; Auer rods are specific.
  • ALL: Most common childhood leukemia; lymphoblasts are TdT positive.
  • CLL: Most common adult leukemia; features Smudge cells, potential Richter's transformation.
  • Burkitt Lymphoma: Associated with EBV, t(8;14) (c-myc), shows starry sky histology.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Hematological Malignancies

Test your understanding with these related questions

A 69-year-old Caucasian man presents for a routine health maintenance examination. He feels well. He has no significant past medical history. He takes aspirin for the occasional headaches that he has had for over several years. He exercises every day and does not smoke. His father was diagnosed with a hematologic malignancy at 79 years old. The patient’s vital signs are within normal limits. Physical examination shows no abnormalities. The laboratory test results are as follows: Hemoglobin 14.5 g/dL Leukocyte count 62,000/mm3 Platelet count 350,000/mm3 A peripheral blood smear is obtained (shown on the image). Which of the following best explains these findings?

Image for question 1
1 of 5

Flashcards: Hematological Malignancies

1/10

What is the most powerful prognostic indicator of multiple myeloma at the time of diagnosis?_____

TAP TO REVEAL ANSWER

What is the most powerful prognostic indicator of multiple myeloma at the time of diagnosis?_____

2 microglobulin

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Hematological Malignancies - Free Indian Medical PG Review